Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 8von Hippel-Lindau Disease 3Pheochromocytoma 2Paraganglioma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Metastatic Castration-Resistant Prostate Cancer 1Kidney Neoplasms 1Hemangioblastoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

pembrolizumab 48Specimen Handling 29Magnetic Resonance Spectroscopy 25Biopsy 25Radiosurgery 17Gemcitabine 17Nivolumab 16Cyclophosphamide 14Cisplatin 14Paclitaxel 13Carboplatin 13Bevacizumab 12Drug Therapy 11Taxes 10Radiotherapy 10Oxaliplatin 10Leucovorin 10Irinotecan 10Fluorouracil 10Capecitabine 10trastuzumab deruxtecan 9fludarabine 9cemiplimab 8Doxorubicin 8Cetuximab 8abemaciclib 7Trastuzumab 7Pemetrexed 7Fulvestrant 7Docetaxel 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Metastasis × belzutifan × Clear all
NCT06234605 2026-01-15

A Study of HC-7366 in Combination With Belzutifan (WELIREGâ„¢) in Patients With Renal Cell Carcinoma

HiberCell, Inc.

Phase 1 Recruiting
80 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡